Cytomegaloviruses (CMVs) are ubiquitous, host-specific pathogens that are capable of establishing lifelong infections in immunocompetent hosts. Although acute infection will elicit an immune response, this response usually fails to completely resolve the infection. Instead, the virus persists in the host, often in a state of latency, and recurrent infections may be observed if the animal becomes immunocompromised (5) . In order to maintain this degree of persistence, especially in the face of a fully primed immune system, CMVs have developed various means of modulating the host immune system. One strategy used by both human and murine CMVs (HCMV and MCMV) is the down-regulation of host class I major histocompatibility complex (MHC) molecules (6) . Class I MHC molecules are polymorphic glycoproteins composed of a membrane-bound heavy chain associated with a nonpolymorphic light chain, ␤2-microglobulin (␤2m). Class I molecules present peptides derived from the degradation of cytoplasmic proteins to cytotoxic T cells, thus enabling them to survey the status of the interior of the cell (49) . In an uninfected cell, MHC molecules bind peptides derived from self proteins to which T cells are tolerant. However, in an infected cell, some MHC molecules are occupied by peptides derived from viral proteins, to which T cells react by killing the cell. By down-regulating MHC class I molecules, viruses are able to elude viral-antigen-specific cytotoxic T cells.
Although interference with class I-mediated antigen presentation or class I expression may enable infected cells to evade virus-specific T cells, it may also render these cells susceptible to detection and lysis by NK cells. NK cells express both activating and inhibitory surface receptors (31) . The activating receptors are predominantly triggered by non-MHC molecules, while the inhibitory receptors recognize class I MHC molecules (31) . Stimulation of activating receptors leads to target cell lysis unless the NK cell inhibitory receptors are able to engage an adequate level of self class I molecules on the target cell (27) . Therefore, those cells that have down-regulated their class I molecules to a level sufficient to avoid T cells can be recognized and eliminated by NK cells.
As a possible means of undermining the host NK cell response, both HCMV and MCMV encode MHC class I homologs (2, 14, 39) . It has been hypothesized that the role of these homologs in a virus-infected cell is to engage NK cell inhibitory receptors, thereby preventing the lysis that would normally occur due to down-regulation of class I molecules (11, 14, 40) . In this way virus-infected cells are less susceptible to lysis by both cytotoxic T lymphocytes and NK cells. The HCMV-encoded homolog, U L 18, is a 348-residue type I transmembrane glycoprotein whose extracellular region shares ϳ25% amino acid sequence identity with the extracellular regions of human class I molecules (2) (Fig. 1A) . Like class I MHC molecules, U L 18 associates with ␤2m (6). We previously showed that a soluble form of U L 18 expressed in Chinese hamster ovary (CHO) cells binds a mixture of endogenous peptides with characteristics similar to those of peptides eluted from class I molecules, that is, "anchor" residues, and a predominance of short peptides derived from cytoplasmic proteins (11) . The MCMV-encoded MHC homolog, m144, is a 383-residue type I transmembrane glycoprotein whose extracellular region shares ϳ25% amino acid sequence identity with the corresponding part of murine class I MHC extracellular re-gions (14, 39) (Fig. 1A) . The two viral homologs are not closely related to each other, sharing only 18% sequence identity, thus requiring that m144 be separately characterized.
In this paper we describe the expression and biochemical characterization of a soluble version of m144. We find that, like U L 18 and class I MHC molecules, m144 binds ␤2m, but unlike these other proteins, it does not associate with endogenous peptides. We further demonstrate that m144 is thermally stable in the absence of bound peptide, unlike both class I MHC molecules (13, 33, 46, 50) and U L 18. Taken together with a sequence comparison of m144 with class I MHC molecules, these results suggest that the m144 counterpart of the MHC peptide-binding site differs from those of both class I molecules and U L 18 (Fig. 1B) .
MATERIALS AND METHODS
Construction of the m144 expression plasmid. Molecular cloning manipulations were performed by standard protocols (43) . PCR was used to insert a 5Ј XhoI site, a 3Ј NotI site, and a stop codon after the codon corresponding to amino acid 241 of the m144 gene (the HindIII fragment I of MCMV strain K181 was kindly provided by Helen Farrell, University of Western Australia, Nedlands). Our numbering scheme starts with the first residue of the mature protein, which is designated residue 1, and all other residues are numbered sequentially (see "N-terminal sequencing of purified m144" below). The PCR product was cloned into pBSIISK ϩ (Stratagene), and the sequence was verified. The modified m144 gene was then removed from pBSIISK ϩ by using XhoI and NotI and was subcloned into the unique XhoI and NotI sites of the expression vector PBJ5-GS (16) . PBJ5-GS carries the glutamine synthetase gene as a selectable marker and as a means of gene amplification in the presence of the drug methionine sulfoximine, a system developed by Celltech (1) .
Construction of the murine ␤2m (b allele) expression plasmid. An expression plasmid containing the a allele of murine ␤2m (m␤2m a ) was previously constructed in our laboratory (12) . This allele of ␤2m, however, is not recognized by the anti-m␤2m monoclonal antibody (MAb) S19.8 (48) . Originally anticipating that m144-m␤2m heterodimers could be purified by S19.8 immunoaffinity chromatography, we used site-directed mutagenesis to change m␤2m a to m␤2m b . This m␤2m a gene was excised by using XbaI and XhoI and was subcloned into the same sites in pBSKSϩ (Stratagene). The a and b alleles of m␤2m differ by only 1 nucleotide, which changes residue 85 from Asp to Ala (15) . The single nucleotide was altered by oligonucleotide-directed in vitro mutagenesis (29) , and the sequence was verified. The modified m␤2m gene was then removed from pB-SKS ϩ by using XbaI and XhoI and was subcloned into the unique XbaI and XhoI sites of the expression vector PBJ1 (32) . Unfortunately, the m␤2m b epitope recognized by the antibody S19.8 is inaccessible when the protein is complexed to the m144 heavy chain, as verified in immunoprecipitation experiments (data not shown).
Cell culture and transfection. The m144 expression plasmid was cotransfected with either a human ␤2m (h␤2m) (13) expression vector or the previously described m␤2m expression vector into CHO cells by a Lipofectin procedure (GIBCO BRL). Cells resistant to 100 M methionine sulfoximine were selected according to the protocol established by Celltech, modification of which has been previously described (16) . Transfected CHO cells were maintained in glutaminefree ␣ minimal essential medium (Irvine Scientific) supplemented with 5% dialyzed fetal bovine serum (GIBCO BRL), 100 M methionine sulfoximine (Sigma), penicillin (100 U/ml), and streptomycin (100 g/ml). Cells secreting m144-␤2m heterodimers were identified by immunoprecipitation of supernatants of cells metabolically labeled with [ 35 S]methionine and [ 35 S]cysteine (see below) by using either an antibody against h␤2m (BBM.1) (36) or anti-m144 antiserum. Clones were considered positive if immunoprecipitation yielded a heavy chain of 44 kDa and a light chain of 12 kDa. The heavy chain was verified to be m144 by N-terminal sequencing (see below).
35 S metabolic labeling. m144-transfected CHO cell lines derived from colonies were expanded into 12-well trays, grown to confluence, and incubated for 5 h in 1.0 ml of methionine-and cysteine-free medium (GIBCO BRL) plus 1% dialyzed fetal bovine serum including 5 Ci of a [
35 S]methionine and [ 35 S]cysteine (ICN) mixture. Supernatants were clarified by a 5-min spin in a microcentrifuge, and either BBM.1 or anti-m144 antiserum (see below) was added. Immunoprecipitations were carried out by standard methods (21) with protein G-bearing Sepharose beads (Pharmacia). Samples were boiled in sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) running buffer and loaded onto 15% polyacrylamide gels, which were fixed, dried, and exposed to a Phosphor- . Numbering is with reference to class I MHC molecules. Crystallographically determined secondary-structural elements in class I MHC molecules (3) are shown above the sequences as arrows for ␤ strands (strands 1 through 8 within the ␣1 and ␣2 domains are labeled ␤1 to ␤8, and strands 1 through 7 within the ␣3 domain are labeled A to G) and spirals for ␣-helical regions. Positions of conserved tyrosines in the pocket that accommodates peptide N termini (pocket A in class I MHC molecules [45, 47] ) are marked with an asterisk, and potential N-linked glycosylation sites are underlined. (B) Locations of U L 18 and m144 sequence insertions and deletions on the class I MHC structure. Ribbon diagrams of the carbon-␣ backbone of the ␣1 and ␣2 domains of HLA-A2 (4, 45) are shown with the locations of U L 18 or m144 insertions indicated by asterisks; class I regions that are deleted in U L 18 or m144 are indicated by dashed lines. Conserved tyrosines shared between U L 18 and class I molecules are highlighted in the left panel. This figure was generated by using Molscript (28) and Raster-3D (34).
Imager screen (Molecular Dynamics). The image was then developed with a Molecular Dynamics 425E phosphorimage scanner.
Protein purification. m144-h␤2m-and m144-m␤2m-secreting CHO cell lines were grown to confluence in 50 10-cm plates. Supernatants were collected every 3 days for 1 month. Soluble m144-h␤2m heterodimers were purified from the supernatants on a BBM.1 immunoaffinity column. This affinity column was prepared by coupling 70 mg of the BBM.1 MAb to cyanogen bromide-treated Sepharose 4B (Pharmacia) at approximately 10 mg of antibody/ml of resin according to the protocol of the manufacturer. Supernatants were passed over the affinity column, which was then washed with 50 column volumes of a solution consisting of 50 mM Tris (pH 7.4), 0.1% NaN 3 , and 1 mM EDTA. Free ␤2m and m144-h␤2m heterodimers were eluted from the BBM.1 column with 50 mM diethylamine (pH 11.5) into tubes containing 1.0 M Tris (pH 7.4). Free h␤2m was separated from m144-h␤2m heterodimers by using a Superdex 200 HR 10/30 fast protein liquid chromatography (FPLC) filtration column. Approximately 3 mg of m144-h␤2m heterodimers was recovered per liter of transfected cell supernatants. Soluble m144-m␤2m heterodimers were purified from the supernatants on a 15C6 immunoaffinity column made by coupling an anti-m144 MAb (see below) to Sepharose beads as described above. Supernatants from m144-m␤2m-secreting CHO cell lines were passed over the column, the column was washed, and the protein was eluted as described above. A second protein migrating with an apparent molecular mass of 93 kDa coeluted with the m144-m␤2m heterodimer and was separated by using a Superdex 200 HR 10/30 FPLC filtration column. Approximately 1 mg of m144-m␤2m heterodimer was recovered per liter of transfected cell supernatants.
N-terminal sequencing of purified m144. N-terminal sequencing was performed on 2.3 g of purified soluble m144-h␤2m or m144-m␤2m in a phosphate buffer dried onto a poly(vinylidene difluoride) membrane and inserted into an Applied Biosystems model 476A sequencer reaction cartridge. Two sequences were isolated from the m144-h␤2m sample: the sequence IQRTPKIQVYSRH PAEN, corresponding to the first 17 residues of mature h␤2m (26) , and the sequence HGTEDSSESGLRYAYT, corresponding to the first 17 residues of the mature m144 heavy chain (reference 14 and data not shown). Two sequences were also isolated from the m144-m␤2m sample: the sequence IQKTPQIQVYS RHPPEN, corresponding to the first 17 residues of mature m␤2m (17) , and the residues given above for the m144 heavy chain.
Acid elution and characterization of peptides. Purified secreted U L 18, m144-h␤2m, m144-m␤2m, FcRn (a class I MHC homolog that functions as a receptor for the Fc portions of immunoglobulin G [16] ), and H2-K d -h␤2m (a murine class I MHC heavy chain complexed with h␤2m [13] ) proteins were analyzed for the presence of bound peptides. All these proteins were produced in CHO cells as described above for m144. In these experiments, FcRn served as the negative control, since it had previously been established by biochemical and crystallographic methods that it does not associate with endogenous peptides (7, 37) , while U L 18 and K d served as positive controls, since endogenous peptides had previously been characterized from samples of these proteins (11, 37) . Acid elutions and sequencing were performed by established methods (24, 42, 51) . Briefly, 0.25 mg of protein was concentrated to 100 l in a Centricon 3 (molecular weight cutoff, 3,000) ultrafiltration device (Amicon; Beverly, Mass.). After dilution with 1.0 ml of 50 mM ammonium acetate (pH 7.5), the proteins were again concentrated to 100 l, and this procedure was repeated. The washed protein was then treated with 1.0 ml of 12% acetic acid, heated to 70°C for 5 min, and subsequently concentrated again to 100 l in the ultrafiltration unit, with the filtrate containing any eluted material. This elution step was then repeated. The acid eluates were lyophilized and analyzed by automated Edman degradation with an Applied Biosystems model 476A protein sequencer (see Table 1 ). Eluates were also analyzed with a Perkin-Elmer/Applied Biosystems Inc. model 172A microbore high-pressure liquid chromatograph (HPLC) and a Reliasil C 18 (Reliasil Column Engineering) column. Material was eluted by using a 3-ml gradient from 0.05% trifluoroacetic acid in water to 0.05% trifluoroacetic acid in 40% acetonitrile. Absorbance was monitored at 200 nm. The fractions containing peaks were analyzed by matrix-assisted, laser desorption, time-of-flight mass spectrometry with a PerSeptive Biosystems (Farmingham, Mass.) ELITE mass spectrometer.
CD analyses. An Aviv 62A DS spectropolarimeter equipped with a thermoelectric cell holder was used for circular dichroism (CD) measurements. Wavelength scans and thermal denaturation curves were obtained from samples containing 10 M protein in 5 mM phosphate at pH 7 by using a 0.1-mm path length cell for wavelength scans and a 1-mm path length cell for thermal denaturation measurements. The heat-induced unfolding of U L 18, m144-h␤2m, m144-m␤2m, and H2-K d -h␤2m was monitored by recording the CD signal at 223 nm while the sample temperature was raised from 25 to 75°C at a rate of approximately 0.7°C/min. The transition midpoint (T m ) for each curve was determined by taking the maximum of a plot of d/dT versus T (where is ellipticity) after averaging the data with a moving window of 5 points.
Production of MAbs and polyclonal antiserum. Three MAbs were generated for the studies presented here, two specific for m144-␤2m and one specific for the U L 18 heavy chain. Of those that recognize m144-␤2m, 15C6 was raised against a gel slice of the m144 heavy chain and 19G4 was raised against the m144-h␤2m heterodimer. Female BALB/c mice (5 weeks old) were primed and twice boosted at 2-week intervals by intraperitoneal injection of either a 5-by 10-by 1.5-mm homogenized gel slice containing m144 or 100 g of purified soluble m144-h␤2m. Serum was screened 1 week after each injection by enzyme-linked immunosorbent assay (ELISA). Three days preceding the fusion, one mouse was boosted with a gel slice or 100 g of purified m144 in phosphate-buffered saline. Splenocytes from the boosted mouse were fused with HL-1 murine myeloma cells, and media from the hybridoma cultures were tested for antibodies against the m144 heavy chain by ELISA. After subcloning of positive clones at clonal density, ascites tumors were produced in pristane-primed BALB/c mice. In addition, a rabbit antiserum recognizing m144 was raised against a gel slice of the m144 heavy chain (Antibodies Incorporated, Davis, Calif.). Both MAbs and the antiserum are effective reagents in an ELISA for detection of m144-␤2m, immunoprecipitation of soluble m144-␤2m heterodimers, and Western blotting. The U L 18-specific MAb, 10C7, was prepared similarly to m144-specific MAbs; however, the mice used were female OLA ϫ BL6 h␤2m transgenic mice (a kind gift of H. Ploegh, Massachusetts Institute of Technology) injected with enzymatically deglycosylated U L 18-h␤2m heterodimers. Several previous attempts to isolate an antibody against the U L 18 heavy chain in nontransgenic mice failed, presumably because U L 18 is heavily glycosylated (13 potential N-linked glycosylation sites [2] ), so that an antibody recognizing a protein epitope within U L 18 rather than ␤2m was difficult to isolate. Indeed, all hybridomas screened from nontransgenic mice produced antibodies that recognized h␤2m instead of the heavy chain. By using h␤2m transgenic mice, many potential MAbs against the heavy chain were generated. A rabbit antiserum recognizing U L 18 was raised against a gel slice of the U L 18 heavy chain (HRP Inc., Denver, Pa.). Both the MAb and the antiserum are effective reagents in an ELISA for detection of U L 18-h␤2m, immunoprecipitation of soluble U L 18-h␤2m heterodimers, and Western blotting.
Preparation of peptide-filled U L 18 and H-2K d . U L 18 was purified from the supernatants of U L 18-h␤2m-secreting cells (11) grown in a hollow-fiber bioreactor device (Cell Pharm I; Unisyn Fibertec, San Diego, Calif.). Using this system, only 35 to 40% of the molecules appear to contain endogenous peptides, compared to U L 18 produced from transfected cells grown on plates, which appears to be fully occupied (11) . As previously described (11) 
RESULTS
Soluble m144 associates with h␤2m and m␤2m. To investigate whether m144 binds ␤2m and serves as a peptide receptor, we expressed a soluble version of m144 in CHO cells together with h␤2m or m␤2m. The soluble version of m144 was constructed by truncating the gene prior to the predicted transmembrane region (following residue 241 of the mature protein). Initial experiments were performed with the h␤2m gene in order to facilitate detection of the protein product with the antibody BBM.1 (36) , which binds to h␤2m but not to m␤2m. Transfected cells were screened by immunoprecipitating metabolically labeled supernatants with BBM.1. SDS-PAGE analysis of protein from positive clones revealed two bands, one having an apparent molecular mass of 45 kDa (consistent with its identity as truncated m144) and the other having an apparent molecular mass of 12 kDa, corresponding to ␤2m. The calculated molecular mass of truncated m144 is 27 kDa, but the protein is glycosylated (4 potential N-linked glycosylation sites [14, 39] ) and would be expected to migrate with a higher apparent molecular mass. Supernatants from positive clones were passed over a BBM.1 immunoaffinity column, eluted, then passed over a size exclusion column to separate free ␤2m from ␤2m-heavy chain heterodimers. An SDS-PAGE gel of the resulting purified protein is shown in Fig. 2 . N-terminal sequencing of purified heterodimers confirmed the sequences of the first 17 residues of the mature forms of h␤2m (26) and m144 (14, 39) .
Soluble m144 was used to produce MAbs that could be used to recognize m144 when complexed with m␤2m. Two antibodies were produced: 15C6, which was raised against a gel slice of the m144 heavy chain, and 19G4, which was raised against purified m144-h␤2m heterodimers. CHO cells were transfected with genes encoding truncated m144 and the b allele of m␤2m. Cells expressing m144-m␤2m heterodimers could be identified by immunoprecipitation with either the anti-m144 MAbs or a polyclonal anti-␤2m antiserum that recognizes m␤2m, but not by immunoprecipitation with the MAb S19.8 (48) , which apparently does not react with m␤2m b complexed with m144. SDS-PAGE analysis of immunoprecipitated protein from cells expressing m144 and m␤2m also reveals two bands migrating at 45 and 12 kDa (data not shown). m144-m␤2m was purified from transfected cell supernatants on an immunoaffinity column constructed with MAb 15C6 (Fig. 2) . N-terminal sequencing of purified protein established that the heterodimer was composed of the mature forms of m144 and m␤2m. Sequences of hamster (16) and bovine (20) ␤2m were not detected, indicating that m144 was not associating with endogenous hamster ␤2m or exchanging with bovine ␤2m in the medium, as can occur when mouse class I MHC proteins are expressed with m␤2m in CHO cells (13) . m144 does not bind endogenous peptides. To determine if either m144-h␤2m or m144-m␤2m binds peptides, purified proteins were treated with acetic acid to dissociate potential peptide material (24, 42, 51) . Acid eluates were characterized by N-terminal sequencing (see Table 1 ), HPLC, and mass spectrometry. Soluble versions of other proteins expressed in CHO cells (the murine class I MHC molecule H2-K d and two other MHC class I homologs, U L 18 from HCMV and the rat neonatal Fc receptor, FcRn) were subjected to the same treatment. K d and U L 18 had previously been shown to bind peptides and were used as positive controls (10, 11, 37) . FcRn does not bind peptides (7, 37) and was used as a negative control.
The characteristics of the peptides isolated from K d and U L 18 were similar to those previously reported (11, 37) and consistent with the known requirement for a tyrosine anchor at position 2 for K d (38) and a leucine or methionine anchor at position 2 for U L 18 (11) ( Table 1 ). An aliquot of the U L 18 acid eluate was passed over a reverse-phase HPLC column, several peaks were collected, and a number of these were characterized by mass spectrometry. This procedure resulted in identification of multiple peptides in the U L 18 acid eluate whose exact molecular weights corresponded to the sequences of peptides previously shown to be associated with U L 18 (reference 11 and data not shown).
By contrast, the low-molecular-weight acid eluates from m144-h␤2m, m144-m␤2m, and FcRn did not show the presence of peptides (Table 1) . With the exception of cycle 1, which is typically subject to high backgrounds, the total yield of the amino acids from each cycle of pool sequencing of the acid eluates remained nearly constant, and this yield was only slightly above background. In addition, most of the peaks in the HPLC profile of the m144-h␤2m acid eluate were also apparent in eluates extracted from FcRn, and all were barely notable above the background. When the few peaks that differed between the m144-h␤m and FcRn eluates were collected and characterized by mass spectrometry, these peaks were found to contain low-molecular-weight material that did not show proteinaceous characteristics (data not shown).
m144, but not U L 18, is thermally stable in the absence of peptides. Class I MHC heavy chains show decreased stability in the absence of bound peptide (13, 33, 50) . To ascertain if m144-h␤2m or m144-m␤2m is unstable due to the absence of bound peptide, we monitored the heat-induced unfolding of these proteins by recording the CD signal at 223 nm while increasing the sample temperature from 25 to 75°C (Fig. 3A) . The results were compared with melting curves of partially empty and peptide-filled forms of the class I MHC molecule H-2K d (Fig. 3B ) (13) . Two unfolding transitions are evident in the curve derived from m144-h␤2m. The first, with a T m of 55°C, corresponds to the unfolding of the m144 heavy chain, while the second, with a T m of 64°C, corresponds to the previously observed T m for h␤2m (13) and represents the independent unfolding of the light chain subsequent to heavy-chain denaturation. m144-m␤2m melts less cooperatively than m144-h␤2m and the derived T m for the heavy-chain unfolding (52°C) is slightly lower, indicating that m144 complexed with m␤2m is somewhat less stable than m144 complexed with h␤2m. In addition, the downward-sloping transition for the melting of ␤2m is not apparent in the melting curve of m144-m␤2m, perhaps being obscured by the CD signal from the melted m144 heavy chain. Similar results were obtained for the melting of K d complexed with m␤2m (12) . The melting behavior of   FIG. 2 . SDS-PAGE (15% polyacrylamide) analysis of U L 18 and the two forms of m144. Proteins were purified from the supernatants of transfected CHO cells by passage over an immunoaffinity column followed by size exclusion chromatography. The heavy chains of both heterodimers migrate with a higher apparent molecular mass than is suggested by the mass of their protein backbones due to the addition of N-linked glycosides (U L 18 contains 13, and m144 contains 4, potential N-linked glycosylation sites). a The total yield of amino acids from each sequencing cycle is presented for acid eluates derived from equivalent amounts of soluble U L 18, K d -h␤2m, FcRn, m144-h␤2m, and m144-m␤2m heterodimers. Only those amino acid residues that showed an increase in the absolute amount recovered compared to the previous cycle were considered significant. Results for the FcRn, K d , and U L 18 eluates are similar to those previously reported (11, 37) in which soluble U L 18 and K d , but not FcRn, were shown to bind endogenous peptides.
b Acid elution contributions from Asp, Glu, and Gly were not included in the m144-m␤2m tabulation because the first four cycles showed unusually high yields that were also present in the negative control. both forms of m144 is more similar to that of peptide-filled Fig. 3A and B) , suggesting that m144 is thermally stable in the absence of peptide.
By contrast, thermal-stability profiles of U L 18 indicate that U L 18 is only marginally stable in the absence of added peptide (Fig. 3C) . The U L 18 protein produced from transfected CHO cells grown in a hollow-fiber bioreactor is estimated to be only 40% occupied with endogenous peptide (see Materials and Methods). This form of U L 18 melts with a T m of 41°C. Upon addition of a known U L 18-binding peptide (11), the T m increases to 66°C (Fig. 3C) .
CD spectral comparison of m144, U L 18, FcRn, and class I MHC. The far-UV CD spectrum of m144 was compared with spectra of other MHC homologs and a classical class I molecule (Fig. 4) . Far-UV CD spectra were previously used to characterize the secondary structures of class I MHC molecules and FcRn (16, 18, 30) . The available crystal structures of FcRn and class I molecules (7, 47) can be used to verify the conclusion derived from the CD spectra that the secondarystructure arrangement of FcRn resembles, but is not identical to, class I MHC structures. The spectra of all four molecules (m144-h␤2m, U L 18, FcRn, and H-2K d ) show characteristics of proteins that are composed primarily of ␤-structure with a minor ␣-helical conformation (25) . However, the short-wavelength portion of the m144 spectrum is red-shifted compared with the H-2K d and U L 18 spectra and with part of the FcRn spectrum. These results suggest that m144 has structural features that distinguish it from U L 18 and classical class I molecules. Since all three types of proteins share the common feature of ␤2m binding, it is likely that structural differences are localized to regions distal from ␤2m, such as the top surface of the ␣1␣2 platform (Fig. 1) .
DISCUSSION
HCMV and MCMV both encode class I MHC homologs. Previous studies indicated that U L 18, the HCMV class I homolog, binds the class I light chain ␤2m (6) and associates with endogenous peptides (11) . In this study, we expressed a soluble version of the MCMV class I homolog m144 and compared its biochemical characteristics to those of class I molecules and U L 18. We found that m144 expressed in CHO cells associates with both h␤2m and m␤2m, implying that m144 heterodimerizes with host-derived ␤2m in virus-infected cells. However, unlike U L 18 and class I molecules, m144 does not bind endogenous peptides, since we do not detect peptide material associated with either form of m144-␤2m. Other class I MHC homologs for which biochemical or structural studies do not reveal the presence of endogenous peptides include FcRn (7, 37) , human Zn-␣2-glycoprotein (44) , and the hemochromatosis gene product HFE (31a). In addition, human MICA and mouse H-2T region-encoded molecules are stably expressed in cells that lack a functional peptide transporter, suggesting that they too do not bind conventional class I peptide ligands (9, 19, 23, 52) .
A comparison of alignments of the m144 and U L 18 sequences with class I MHC sequences reveals that U L 18 is more likely than m144 to adopt a fold that includes an MHC-like peptide-binding groove (Fig. 1B) . Peptides bind to class I MHC molecules in a groove located between two ␣-helices that span an 8-stranded ␤-pleated sheet. Peptide termini are accommodated in pockets at each end of the groove that are lined with conserved residues (reviewed in reference 47). The peptide N terminus binds in pocket A on the left side of the groove (as depicted in Fig. 1B) , in which four conserved tyrosines make critical hydrogen bonds to main-chain atoms of the peptide (residues 7, 59, 159, and 171; class I numbering) (Fig. 1A) . These tyrosines are also found in the U L 18 sequence, suggesting a similar mechanism for interaction with peptide N termini (11) . While the U L 18 sequence shows some gaps and insertions compared to class I sequences, these are primarily confined to regions corresponding to the right side of the groove and suggest that the U L 18 structure may differ from MHC structures in the region of the groove that interacts with peptide C termini. Indeed, analysis of endogenous peptides associated with U L 18 revealed variability in the length of bound peptides (11), whereas classical class I molecules show a strong preference for binding octamer and nonamer peptides (reviewed in reference 47). By contrast, only two of the four pocket A tyrosines are conserved in the m144 sequence (Fig.  1A) . Furthermore, the ␣2 domain of m144 is significantly truncated compared to those of class I and U L 18 molecules, such that ␤ strands 6 and 8 are much shorter, there is no predicted seventh strand, and there is a large deletion within the predicted ␣2 domain helix. These characteristics do not seem compatible with formation of a functional peptide-binding groove, and they imply that this region of m144 is structurally distinct from class I molecules and U L 18. Far-UV CD spectral differences support this prediction (Fig. 4) .
Our finding that m144, unlike class I MHC molecules and U L 18, is thermally stable in the absence of bound peptide is also consistent with a structural rearrangement in the counterpart of its peptide-binding region. CD melting curves of m144 complexed with either h␤2m or m␤2m show that it is more stable than either an empty class I molecule or partially empty U L 18 (Fig. 3) . The melting curves of the empty forms of class I and U L 18 were characterized by T m s between 42 and 45°C, while the T m of the m144-h␤2m curve was 55°C, closer to the T m for peptide-filled K d (56 to 57°C) (12, 13) . m144 is slightly less stable when complexed with m␤2m (T m ϭ 52°C). This effect was also noted for the complex of m␤2m with K d , compared with the complex of h␤2m with K d (12) , and more dramatically, for the complex of m␤2m with the nonclassical murine class I protein T10 (9) . We were able to analyze the effect of bound peptide on U L 18 stability by taking advantage of the fact that soluble U L 18 is only partially occupied with endogenous peptides when it is expressed at high levels. Addition of a synthetic peptide corresponding to the sequence of an endogenous peptide eluted from U L 18 shifts the T m to 66°C, thus formally demonstrating that U L 18 binds this peptide and suggesting a general method for assaying peptide binding by U L 18.
The different properties of U L 18 and m144 revealed by this study do not, in and of themselves, undermine the contention that these molecules both function as surrogate class I proteins, capable of engaging NK cell inhibitory receptors and protecting cells that lack class I surface expression. Murine NK cell inhibitory receptors are homodimeric C-type lectin superfamily proteins, whereas the majority of characterized human inhibitory receptors are members of the immunoglobulin superfamily (reviewed in references 22 and 35) . It is therefore conceivable that mouse NK inhibitory receptors would recognize features of mouse class I MHC molecules different from those recognized on human class I molecules by human inhibitory receptors. While there is no evidence yet of a direct interaction between a mouse inhibitory receptor and m144, recent results demonstrate that the presence of m144 interferes with NK cell-mediated clearance of virus-infected cells in vivo (14) . The connection between U L 18 and human NK cells is less straightforward. A recent study reported that U L 18 expressed on a human class I-negative B-lymphoblastoid cell line inhibited NK cell lysis through interaction with the Clectin-like inhibitory receptor CD94 (40) . However, we and investigators at other laboratories have been unable to detect cell surface expression of U L 18 when its gene was transfected into the same B-cell line (31b). Additional results indicate that the presence of U L 18 on virus-infected fibroblasts slightly augments, rather than inhibits, NK cell-mediated lysis (31b). A probable host ligand for U L 18 was recently identified as LIR-1, a new immunoglobulin superfamily member related to human NK inhibitory receptors (8) . LIR-1 is expressed mainly on B cells and monocytes, but only on a subset of NK cells; thus, it is possible that the HCMV MHC homolog exerts its primary effects on host cells other than NK cells. Further studies will be necessary to resolve the roles of both m144 and U L 18 in the interactions of their respective viruses with the immune systems of the infected hosts. However, currently available data suggest that the two homologs function differently, a hypothesis that is consistent with the biochemical and structural differences between m144 and U L 18 observed in the present study. 
